Keywords
triiodothyronine
thyroxin
course of the disease
regression model
How to Cite
Abstract
We examined 157 patients with heart failure (HF) – myocardial infarction, in which predictors of an unfavorable course of the disease were determined depending on thyroid status. During hospitalization, a standardized assessment of the condition was carried out, indicators of intracardiac hemodynamics, clinical and biochemical blood tests, and levels of thyroid hormones were determined. It was established that the risk of re-hospitalization of patients with heart failure due to decompensation of the disease increases when the optimal separation point is exceeded for serum free triiodothyronine level ≤ 2,07 pmol/l. The relative risk of re-hospitalization of patients with heart failure within 2 years at a level of free triiodothyronine ≤ 2,07 pmol/l is 2,224 [1,333–3,630] (p<0,05). Using automatic regression analysis, a model for re-hospitalization of patients with heart failure due to decompensation of the disease for 2 years was built. It included the following indicators: body weight, the level of free triiodothyronine, the presence of non-toxic goiter, cholesterol levels of low density lipoproteins and total cholesterol, the relative content of granulocytes in the blood, the concentration of free thyroxine. According to the ROC analysis, the risk of re-hospitalization of patients with heart failure due to decompensation of the disease increases when the optimal separation point is exceeded for the value of the regression model equation ≥ 1,321 conv. units. Due to the fact that a decrease in the serum level of triiodothyronine affects the course of HF, we can assume that it is advisable to use its value ≤ 2,07 pmol/l as a predictor of the adverse course of the disease.
References
Hamilton M.A., Stevenson L.W., Luu M., Walden J.A. (1990). Altered thyroid hormone metabolism in advanced heart failure. J. Am. Coll. Cardiol., vol. 16 (1), pp. 91–95.
Kozdag G., Ural D., Vural A., Agacdiken A., Kahraman G., Sahin T. et al. (2005). Relation between free triiodothyronine / free thyroxine ratio, echocardiographic parameters and mortality in dilated cardiomyopathy. Eur. J. Heart Fail., vol. 7 (1), pp. 113–118.
Opasich C., Pacini F., Ambrosino N., Riccardi P.G., Febo O., Ferrari R. et al. (1996). Sick euthyroid syndrome in patients with moderate-to-severe chronic heart failure. Eur. Heart J., vol. 17 (12), pp. 1860–1866.
Passino C., Pingitore A., Landi P., Fontana M., Zyw L., Clerico A. et al. (2009). Prognostic value of combined measurement of brain natriuretic peptide and triiodothyronine in heart failure. J. Card. Fail., vol. 15 (1), pp. 35–40, DOI 10.1016/j.cardfail.2008.08.008.
Pingitore A., Landi P., Taddei M.C., Ripoli A., L’Abbate A., Iervasi G. (2005). Triiodothyronine levels for risk stratification of patients with chronic heart failure. Am. J. Med., vol. 118, pp. 132–136, DOI 10.1016/j.amjmed.2004.07.052.
Rudik Yu.S., Pivovar S.N., Biletskaia O.M. (2013). Kardioprotektivnyie mekhanizmy hormonov shchitovidnoi zhelezy [Cardioprotective mechanisms of thyroid hormones]. Ukrainskyi terapevtychnyi zhurnal – Ukrainian Therapeutic Journal, № 3, pp. 95–102 [in Russian].
Ponikowski Р., Voors А.А., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S. et al. (2016). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2016. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart J., vol. 37 (27), pp. 2129–2200, DOI 10.1093/eurheartj/ehw128.
Rothberger G.D., Gadhvi S., Michelakis N., Kumar A., Calixte R., Shapiro L.E. (2017). Usefulness of serum triiodothyronine (T3) to predict outcomes in patients hospitalized with acute heart failure. Am. J. Cardiol., vol. 119 (4), pp. 599–603, DOI 10.1016/j.
Xue C., Bian L., Xie Y.S., Yin Z.F., Xu Z.J., Chen Q.Z. et al. (2017). Low fT3 is associated with diminished health-related quality of life in patients with acute coronary syndrome treated with drug-eluting stent: a longitudinal observational study. Oncotarget, vol. 8 (55), pp. 94580–94590, DOI 10.18632/ oncotarget.21811.
Danzi S., Klein I. (2014). Thyroid disease and the cardiovascular system. Endocrinol. Metab. Clin. North Am., vol. 43, pp. 517–528, DOI 10.1089/105072502760143836.
Gerdes A.M., Ojamaa K. (2016). Thyroid hormone and cardioprotection. Compr. Physiol., vol. 6 (3), pp. 1199–1219, DOI 10.1002/cphy.c150012.
Tomohiro Hayashi, Takuya Hasegawa, Hideaki Kanzaki, Akira Funada, Makoto Amaki, Hiroyuki Takahama et al. (2016). Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure. ESC Heart Fail., vol. 3 (3), pp. 168–176, DOI 10.1002/ehf2.12084.
Gao R., Liang J.-H., Wang L., Zhu H.Y., Wu W., Wu J.Z. et al. (2017). Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma. British Journal of Haematology, vol. 177 (1), pp. 95–105, DOI 10.1111/bjh.14528.
Shanoudy H., Soliman A., Moe S. (2001). Early manifestations of «sick euthyroid» syndrome in patients with compensated chronic heart failure. J. Card. Fail., vol. 7 (2), pp. 146–152, DOI 10.1054/jcaf.2001.24665.